Delhi High Court on Monday in an interim order restrained generic drug maker Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet, which is allegedly identical or deceptively similar to Sun Pharma Laboratories' registered mark for its anti-diabetes drug «Istamet XR CP». Sun Pharma and Glenmark are contesting over their right to use drug names «Istamet» and «Indamet», respectively, which Sun Pharma finds to be deceptively similar and confusing.
Read more on economictimes.indiatimes.com